Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cinqair

- PMLiVE

Gilead settles patent dispute with Teva over Viread generic

Launch of generic HIV drug held back until December 2017

- PMLiVE

GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

- PMLiVE

Global counterfeit drug business driven by crime and corruption

Institute of Medicines says international cooperation needed to tackle falsified medicines

- PMLiVE

Genzyme’s Richard Moscicki joins FDA

Provides regulatory agency with more than 20 years of industry experience

- PMLiVE

FDA fast-tracks Bayer’s prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin

- PMLiVE

Teva wins challenge to BMS’ Baraclude patent in US

US court says hepatitis B treatment’s patent is invalid

- PMLiVE

Bayer submits oral PAH drug riociguat for approval

Set to challenge Actelion and Gilead

- PMLiVE

Lilly abandons tabalumab for rheumatoid arthritis

Decision based on lack of efficacy in late-stage trials

- PMLiVE

Celgene gets US green light for blockbuster candidate Pomalyst

FDA approval to treat multiple myeloma

- PMLiVE

FDA proffers guidance for new Alzheimer’s drugs

Encourages approach that tackles disease in its early stages

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links